The Native Antigen Co. has introduced a line of coronavirus antigens from the emerging Wuhan strain, a move it said will support research and the development of diagnostics and vaccines.
The antigens were derived from the novel coronavirus (2019-nCoV) using the company's proprietary VirtuE expression system. The system introduces proper protein folding and post-translational modifications to recombinant proteins, which are essential for full biological and antigenic activity, according to the company.
